{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:33:02Z","timestamp":1761489182641},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.2515\/therapie\/2013023","type":"journal-article","created":{"date-parts":[[2013,7,25]],"date-time":"2013-07-25T13:47:14Z","timestamp":1374760034000},"page":"149-154","source":"Crossref","is-referenced-by-count":3,"title":["Drugs and Cancer: an Analysis of the French Pharmacovigilance Database"],"prefix":"10.1016","volume":"68","author":[{"given":"Genevi\u00e8ve","family":"Durrieu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Mazau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00e9mi","family":"J\u00e9gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryse","family":"Lapeyre-Mestre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Delord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Louis","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.2515\/therapie\/2013023_bb0310","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1136\/ard.2008.094904","article-title":"Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials","volume":"68","author":"Bongartz","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.2515\/therapie\/2013023_bb0315","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jbspin.2006.09.002","article-title":"Pharmacovigilance for evaluating adverse drug reactions: value, organisation, and methods","volume":"6","author":"Montastruc","year":"2006","journal-title":"Join Bone Spine"},{"key":"10.2515\/therapie\/2013023_bb0320","series-title":"International monitoring of adverse reactions to drugs: adverse reaction terminology","author":"WHO","year":"1992"},{"key":"10.2515\/therapie\/2013023_bb0325","series-title":"Anatomical therapeutic chemical (ATC) classification index","year":"1992"},{"key":"10.2515\/therapie\/2013023_bb0330","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2013023_bb0335","series-title":"\u00c9volution de l\u2019incidence et de la mortalit\u00e9 par cancer en France de 1978 \u00e0 2000","article-title":"R\u00e9seau fran\u00e7ais des registres du cancer, H\u00f4pitaux de Lyon, Institut national de la sant\u00e9 et de la recherche m\u00e9dicale, Institut de veille sanitaire","author":"Remontet","year":"2003"},{"key":"10.2515\/therapie\/2013023_bb0340","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1136\/ard.2009.117762","article-title":"Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registery","volume":"69","author":"Mariette","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.2515\/therapie\/2013023_bb0345","first-page":"295","article-title":"The environment and diseases: association or causation","volume":"58","author":"Hill","year":"1965","journal-title":"Proc R Soc Med"},{"key":"10.2515\/therapie\/2013023_bb0350","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.lpm.2009.02.007","article-title":"What is the risk of malignancies associated with anti-TNF therapy?","volume":"38","author":"Jonville-B\u00e9ra","year":"2009","journal-title":"Presse Med"},{"key":"10.2515\/therapie\/2013023_bb0355","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0300-483X(02)00612-1","article-title":"Immunosuppressive drugs and cancer","volume":"185","author":"Vial","year":"2003","journal-title":"Toxicology"},{"key":"10.2515\/therapie\/2013023_bb0360","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1600-6143.2007.01736.x","article-title":"Cancer incidence among Canadian kidney transplant recipients","volume":"7","author":"Villeneuve","year":"2007","journal-title":"Am J Transplant"},{"key":"10.2515\/therapie\/2013023_bb0365","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1186\/ar2404","article-title":"A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis","volume":"10","author":"Smitten","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.2515\/therapie\/2013023_bb0370","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1158\/1055-9965.EPI-06-0300","article-title":"Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics","volume":"15","author":"Smedby","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.2515\/therapie\/2013023_bb0375","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.critrevonc.2004.11.011","article-title":"Skin cancer and immunosuppression","volume":"56","author":"Gerlini","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.2515\/therapie\/2013023_bb0380","first-page":"919","article-title":"Multiple skin and mouth squamous cell carcinomas related to long-term treatment with hydroxyurea","volume":"128","author":"Est\u00e8ve","year":"2001","journal-title":"Ann Dermatol Venereol"},{"key":"10.2515\/therapie\/2013023_bb0385","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jaad.2003.11.059","article-title":"Hydroxyurea-associated squamous dysplasia","volume":"51","author":"Sanchez-Palacios","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.2515\/therapie\/2013023_bb0390","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1365-2230.2004.01586.x","article-title":"Oral squamous cell carcinoma during long-term treatment with hydroxyurea","volume":"29","author":"De Benedittis","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"10.2515\/therapie\/2013023_bb0395","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1046\/j.1365-2230.2001.00782.x","article-title":"Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia","volume":"26","author":"Vassallo","year":"2001","journal-title":"Clin Exp Dermatol"},{"key":"10.2515\/therapie\/2013023_bb0400","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1177\/1352458507082941","article-title":"Chronic myeloid leukemia associated with mitoxantrone treatment in a patient with MS","volume":"14","author":"Sadiq","year":"2008","journal-title":"Mult Scler"},{"key":"10.2515\/therapie\/2013023_bb0405","first-page":"206","article-title":"Therapy-related acute nonlymphoblastic leukemia following mitoxantrone therapy in a patient with multiple sclerosis","volume":"48","author":"Sumrall","year":"2007","journal-title":"J Miss State Med Assoc"},{"key":"10.2515\/therapie\/2013023_bb0410","series-title":"Volume 9: Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal Therapy","author":"International Agency For Research on Cancer","year":"2007"},{"key":"10.2515\/therapie\/2013023_bb0415","series-title":"Volume 72: Hormonal contraception and post-menopausal hormonal therapy","author":"International Agency For Research on Cancer","year":"1999"},{"key":"10.2515\/therapie\/2013023_bb0420","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/jso.2930280209","article-title":"An apparent danazol-induced primary hepatocellular carcinoma: case report","volume":"28","author":"Buamah","year":"1985","journal-title":"J Surg Oncol"},{"key":"10.2515\/therapie\/2013023_bb0425","first-page":"1447","article-title":"Hepatocellular carcinoma after danazol therapy","volume":"15","author":"Weill","year":"1988","journal-title":"J Rheumatol"},{"key":"10.2515\/therapie\/2013023_bb0430","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0168-8278(98)80140-2","article-title":"Danazol therapy: an unusual aetiology of hepatocellular carcinoma","volume":"29","author":"Crampon","year":"1998","journal-title":"J Hepatol"},{"key":"10.2515\/therapie\/2013023_bb0435","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/qjmed\/hcg050","article-title":"Danazol-induced hepatocellular carcinoma","volume":"96","author":"Confavreux","year":"2003","journal-title":"QJM"},{"key":"10.2515\/therapie\/2013023_bb0440","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1503\/cmaj.060803","article-title":"Does pravastatin promote cancer in elderly patients? A meta-analysis","volume":"176","author":"Bonovas","year":"2007","journal-title":"CMAJ"},{"key":"10.2515\/therapie\/2013023_bb0445","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1200\/JCO.2006.06.3560","article-title":"Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials","volume":"24","author":"Bonovas","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.2515\/therapie\/2013023_bb0450","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1158\/0008-5472.CAN-10-2953","article-title":"Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort","volume":"71","author":"Jacobs","year":"2011","journal-title":"Cancer Res"},{"key":"10.2515\/therapie\/2013023_bb0455","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1158\/1055-9965.EPI-05-0866","article-title":"Statin use and risk of lymphoid neoplasms: results from the European Case-Control Study EPILYMPH","volume":"15","author":"Fortuny","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"Suppl A","key":"10.2515\/therapie\/2013023_bb0460","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S1096-6374(00)90025-X","article-title":"Growth hormone (GH) replacement therapy: cancer in adults treated with GH","volume":"10","author":"Monson","year":"2000","journal-title":"Growth Horm IGF Res"},{"key":"10.2515\/therapie\/2013023_bb0465","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2165\/11590200-000000000-00000","article-title":"Sources of information on lymphoma associated with anti-tumour necrosis factor agents","volume":"34","author":"Th\u00e9ophile","year":"2011","journal-title":"Drug Saf"},{"key":"10.2515\/therapie\/2013023_bb0470","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.2337\/dc10-2412","article-title":"Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting","volume":"34","author":"Piccinni","year":"2011","journal-title":"Diabetes Care"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004059571630909X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004059571630909X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T07:43:53Z","timestamp":1554277433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004059571630909X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S004059571630909X"],"URL":"https:\/\/doi.org\/10.2515\/therapie\/2013023","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}